Spedra 100 mg Tablets
avanafil
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
Spedra contains the active ingredient avanafilo. It belongs to a group of medicines called type 5 phosphodiesterase inhibitors (PDE5). Spedra is a treatment for adult males who suffer from erectile dysfunction (also known as impotence). This occurs when a male is unable to achieve or maintain a firm erection to engage in sexual intercourse.
Spedra works by helping the blood vessels in your penis to relax. This increases blood flow to the penis, helping it to remain hard and erect after sexual stimulation. Spedra does not cure your condition.
It is essential that you know that Spedra only works if you receive sexual stimulation. You and your partner must perform prior sexual stimulation to prepare for sex, just as you would without taking a medication to help you.
Spedra will not help you if you do not suffer from erectile dysfunction. Spedra is not indicated for women.
Do not take Spedra:
Do not take Spedra if you are in any of the above situations. If you are unsure, consult your doctor or pharmacist before taking Spedra.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Spedra:
If you are in any of the above situations, consult your doctor or pharmacist before starting to take Spedra. In case of doubt, consult your doctor or pharmacist.
Visual or auditory problems
Some men who take medications like Spedra have experienced visual and auditory problems, see “Serious adverse reactions”, in section 4 for detailed information. It is not known if these problems are directly related to Spedra, other conditions you may have, or a combination of factors.
If you experience sudden vision loss or loss of vision, or if your vision is distorted or blurred while taking Spedra, stop taking Spedra and contact your doctor immediately.
Children and adolescents
Spedra is not indicated for use in children or adolescents under 18 years old.
Use of Spedra with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication, as Spedra may affect the activity of some medications. Additionally, other medications may affect the activity of Spedra.
Specifically, inform your doctor and do not take Spedra if you are taking medications with “nitrates” for chest pain (angina), such as amyl nitrite or glyceryl trinitrate. It has been shown that Spedra potentiates the effects of these medications and significantly decreases your blood pressure. Do not take Spedra if you are taking medications for HIV or AIDS, such as ritonavir, indinavir, saquinavir, nelfinavir, or atazanavir, or if you are taking medications for fungal infections, such as ketoconazole, itraconazole, or voriconazole, or certain antibiotics for bacterial infections, such as clarithromycin or telithromycin (see the beginning of section 2, “Do not take Spedra”).
Inform your doctor or pharmacist if you are taking any of the following medications:
Do not use Spedra with other treatments for erectile dysfunction, such as sildenafil, tadalafil, or vardenafil.
If you are in any of the above situations, consult your doctor or pharmacist before taking Spedra. In case of doubt, consult your doctor or pharmacist.
Use of Spedra with beverages and alcohol
Orange juice may increase exposure to the medication and should be avoided within 24 hours of taking Spedra.
Consuming alcohol at the same time as Spedra may accelerate heart rate and lower blood pressure. You may feel dizzy (especially when standing), experience headaches, or feel heart palpitations. Alcohol consumption may reduce your ability to achieve an erection.
Fertility
No effects on sperm movement or structure were observed after a single oral dose of 200 mg of avanafilo in healthy volunteers.
Repeated oral administration of avanafilo 100 mg for a period of 26 weeks in healthy volunteers and in men with mild erectile dysfunction did not associate with any adverse effects on sperm concentration, count, motility, or morphology.
Driving and operating machinery
Spedra may cause dizziness or affect your vision. If this occurs, do not drive, ride a bicycle, or use tools or machinery.
In case of doubt, consult your doctor or pharmacist.
The recommended dose is one 100 mg tablet as needed. Do not take Spedra more than once a day. Your doctor may prescribe a 200 mg tablet if they consider the 100 mg dose too weak for you, or a 50 mg tablet if they consider the 100 mg dose too strong. Additionally, the dose may need to be adjusted if Spedra is used with certain medications. If you are taking a medication, such as erythromycin, amprenavir, aprepitant, diltiazem, fluconazole, fosamprenavir, or verapamil (“moderate CYP3A4 inhibitors”), the maximum recommended dose of Spedra is one 100 mg tablet, with an interval of at least 2 days between doses.
Take Spedra approximately 15 to 30 minutes before sexual activity. Remember that Spedra will only help you achieve an erection if you receive sexual stimulation.
Spedra can be taken with or without food. If taken with food, it may take longer to act.
If you take too much Spedra, inform your doctor immediately. You may experience more adverse reactions than usual, and they may be more severe.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, it may cause side effects, although not everyone will experience them.
Severe side effects
Stop taking Spedra and consult a doctor immediately if you notice any of the following severe side effects, as you may require urgent medical treatment:
Stop taking Spedra and consult a doctor immediately if you notice any of the above severe side effects.
Other side effects include:
Frequent (may affect up to 1 in 10 people)
Less common (may affect up to 1 in 100 people):
Rare (may affect up to 1 in 1,000 people)
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not use this medication after the expiration date that appears on the blister pack and on the box after “CAD”: The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the packaging and the medication that you no longer need. In this way, you will help protect the environment.
Composition of Spedra
Appearance of Spedra and contents of the package
Spedra is an oval-shaped yellowish tablet with “100” engraved on one side. The tablets are presented in pre-cut single-dose blisters containing 2x1, 4x1, 8x1, or 12x1 tablets.
Only some package sizes may be marketed in your country.
Marketing Authorization Holder:
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A., 1, Avenue de la Gare, L-1611 Luxembourg, Luxembourg
Manufacturer:
Menarini - Von Heyden GmbH
Leipziger Straße 7-13
01097 Dresden, Germany.
or
Sanofi Winthrop Industrie
1, rue de la Vierge
Ambares et Lagrave
33565 Carbon-Blanc-Cedex
France
You can request more information about this medicine by contacting the local representative of themarketing authorization holder.
België/Belgique/BelgienMenarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: +370 52 691 947 |
Luxembourg/LuxemburgMenarini Benelux NV/SA Tél/Tel: + 32 (0)2 721 4545 | |
Ceská republika Berlin-Chemie/A.Menarini Ceska republika s.r.o. Tel: +420 267 199 333 | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: +36 23501301 |
DanmarkPharmaprim AB Tlf: +46 8355933 | Malta Menarini International Operations Luxembourg S.A. Tel: +352264976 |
Deutschland Berlin-Chemie AG Tel: +49 (0) 30 67070 | Nederland Menarini Benelux NV/SA Tel: +32 (0)2 721 4545 |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: +372 667 5001 | NorgePharmaprim AB Tlf: +46 8355933 |
Ελλ?δα MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | Österreich A. Menarini Pharma GmbH Tel: +43 1 879 95 85-0 |
España Laboratorios Menarini S.A. Tel: +34-93 462 88 00 | Polska Berlin-Chemie/Menarini Polska Sp. z o.o. Tel.: +48 22 566 21 00 |
France MENARINI France Tél: +33 (0)1 45 60 77 20 | Portugal A. Menarini Portugal – Farmacêutica, S.A. Tel: +351 210 935 500 |
Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: + 385 1 4821 361 | România Berlin-Chemie A. Menarini S.R.L. Tel: +40 21 232 34 32 |
Ireland A. Menarini Pharmaceuticals Ireland Ltd Tel: +353 1 284 6744 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: +386 01 300 2160 |
ÍslandPharmaprim AB Sími: +468355933 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o Tel: +421 2 544 30 730 |
Italia A. Menarini Industrie Farmaceutiche Riunite s.r.l. Tel: +39-055 56801 | Suomi/Finland Berlin-Chemie/A.Menarini Suomi OY Puh/Tel: +358 403 000 760 |
Κ?προς MENARINI HELLAS AE Τηλ: +30 210 8316111-13 | SverigePharmaprim AB Tel: +46 8355933 |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel: +371 67103210 | United Kingdom (Northern Ireland) A. Menarini Farmaceutica Internazionale S.R.L. Tel: +44 (0)1628 856400 |
Last update of this leaflet
The detailed information on this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.